On 21st November, Karen Simeson – a nurse working in Pinderfields Hospital – became the first patient in the world to participate in AstraZeneca’s COVID-19 Antibody trial.

The Phase III trial is designed to prevent COVID-19 and will recruit 5,000 patients globally to evaluate the safety and effectiveness of long-acting antibody treatment. The AstraZeneca (AZ) COVID-19 antibody trial is currently being conducted across nine regional sites in the UK. In Wakefield, it is being delivered locally by the Wakefield Together partnership, led by Spectrum CIC with Wakefield Council and NHS partners.

The Antibody Trial

Long-Acting Antibodies mimic natural antibodies and have the potential to treat and prevent disease progression in patients already infected with COVID-19, as well as to be given as a preventative measure prior to exposure to the virus. This trial provides an alternative for patients who may not be suitable for a vaccine (e.g. due to medication or immunosuppression) and offers added protection for high-risk populations. The UK Government has an ‘in principle’ agreement which secures access to one million doses of the antibodies if they are successful in phase III trials.

Sign up now

Volunteers from the Wakefield District are still being recruited for this trial. To volunteer, you must:

  • be aged between 18 to 80
  • have an increased risk of vulnerability to COVID-19 (due to location, employment or personal circumstances) OR be less likely than most adults to benefit from a vaccine (for example, due to older age, obesity or immunosuppression from a health condition or medication).
  • NOT have a previously confirmed diagnosis of COVID-19

Sign up now using the online form at: WFD-Covid19-Trial or call the research team on 07540 305088 and leave a message with your contact details. One of the Trial team will call you back as soon as possible.